Molecular Templates Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Molecular Templates stock.
View analyst ratings for Molecular Templates or view top-rated stocks.

Wall Street analysts have given Molecular Templates a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Molecular Templates wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Molecular Templates is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Molecular Templates.

Molecular Templates, Inc. (NASDAQ:MTEM) issued its quarterly earnings data on Thursday, May, 13th. The biotechnology company reported ($0.51) EPS for the quarter, missing the consensus estimate of $0.31 by $0.82. The biotechnology company earned $3.22 million during the quarter, compared to analysts' expectations of $29.66 million. Molecular Templates had a negative net margin of 611.90% and a negative trailing twelve-month return on equity of 138.03%.
View Molecular Templates' earnings history.

Molecular Templates' stock was trading at $13.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MTEM stock has decreased by 47.0% and is now trading at $7.00.
View which stocks have been most impacted by COVID-19.

Molecular Templates shares reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

4 Wall Street analysts have issued twelve-month price objectives for Molecular Templates' shares. Their forecasts range from $12.00 to $20.00. On average, they anticipate Molecular Templates' share price to reach $14.50 in the next year. This suggests a possible upside of 107.1% from the stock's current price.
View analysts' price targets for Molecular Templates or view top-rated stocks among Wall Street analysts.

Some companies that are related to Molecular Templates include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of MTEM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), CEL-SCI (CVM), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Molecular Templates' stock is owned by many different institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (0.07%). Company insiders that own Molecular Templates stock include Jason S Kim, Kevin M Lalande, Longitude Capital Partners Iii, Scott D Morenstein and Target N V Biotech.
View institutional ownership trends for Molecular Templates.

MTEM stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P.. Company insiders that have bought Molecular Templates stock in the last two years include Longitude Capital Partners Iii, Scott D Morenstein, and Target N V Biotech.
View insider buying and selling activity for Molecular Templates or or view top insider-buying stocks.

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MTEM stock can currently be purchased for approximately $7.00.

Molecular Templates has a market capitalization of $392.70 million and generates $18.84 million in revenue each year. The biotechnology company earns $-104,920,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

Molecular Templates employs 247 workers across the globe.

Molecular Templates was founded in 2009.

The official website for Molecular Templates is www.mtem.com.

Molecular Templates is headquartered at 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729.

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at (512) 869-1555 or via email at [email protected]